- AFT-58 HARMONIA
HARMONIA is an international, multicenter, randomized, open-label and phase III study.
- Alliance A011801
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1.
- CCTG MA39 TAILOR RT
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy.
- DFCI 21-159 ATEMPT 2.0
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combinations of HER2-directed therapies as a treatment after surgery.
- ECOG-ACRIN EA1181
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery after preoperative chemotherapy and HER2-targeted therapy.
- SWOG S1703
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body.
- SWOG S2007
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases).
